Grufity logo
Grufity logo
RNXT

RNXT - RenovoRx, Inc. Stock Price, Fair Value and News

$0.88-0.01 (-1.12%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

31/100

RNXT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

31/100

RNXT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RNXT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RNXT Price Action

Last 7 days

-1.1%

Last 30 days

7.3%

Last 90 days

-9.3%

Trailing 12 Months

-32.3%

RNXT RSI Chart

RNXT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RNXT Valuation

Market Cap

40.1M

Price/Earnings (Trailing)

-3.27

Price/Sales (Trailing)

35.71

EV/EBITDA

-2.49

Price/Free Cashflow

-3.55

RNXT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RNXT Fundamentals

RNXT Revenue

Revenue (TTM)

1.1M

Rev. Growth (Yr)

185.79%

Rev. Growth (Qtr)

136.55%

RNXT Earnings

Earnings (TTM)

-12.3M

Earnings Growth (Yr)

-45.5%

Earnings Growth (Qtr)

-19.72%

RNXT Profitability

Operating Margin

71.77%

EBT Margin

-994.39%

Return on Equity

-108.91%

Return on Assets

-87.86%

Free Cashflow Yield

-28.18%

RNXT Investor Care

Shares Dilution (1Y)

23.27%

Diluted EPS (TTM)

-0.33

RNXT Alerts

  • 1 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
2025---1.1M
2024----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About RenovoRx, Inc.

RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.
 CEO
 WEBSITEhttps://renovorx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES10

RenovoRx, Inc. Frequently Asked Questions

RNXT is the stock ticker symbol of RenovoRx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of RenovoRx, Inc. is 40.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, RNXT's PE ratio (Price to Earnings) is -3.27 and Price to Sales (PS) ratio is 35.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RNXT PE ratio will change depending on the future growth rate expectations of investors.